Celgene CAR-T Therapy Gets Breakthrough Therapy Designation – Nasdaq
|
Celgene CAR–T Therapy Gets Breakthrough Therapy Designation
Nasdaq Celgene CorporationCELG and partner bluebird bio, Inc. BLUE announced that their chimeric antigen receptor T–cell (CAR-T) therapy candidate, bb2121 targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma … |
